
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is experiencing strong growth momentum with its leading product, Cabometyx, particularly in the first-line renal cell carcinoma (1L RCC) and the expanding second-line neuroendocrine tumor (2L+ NET) markets, which is supported by an increase in market share to 46% in the TRx market. The company is strategically expanding its gastrointestinal sales team to capitalize on this demand and to prepare for the launch of zanzalintinib for colorectal cancer (CRC), further enhancing its product offerings. Additionally, Exelixis maintains a strong balance sheet and has updated its sales estimates for Cabometyx to reflect continued growth, indicating a positive outlook for the company’s financial health and profitability in the coming years.
Bears say
Exelixis Inc. has presented several challenges that contribute to a negative outlook on its stock, most notably a decrease in gross-to-net (GTN) from 30.2% in 3Q25 to 28.5% in 4Q25, attributed to reduced PHS/340B volume. Sales for Cabometyx remained flat sequentially at $545 million, underperforming against estimates, which raises concerns regarding the potential for growth amid increasing competition in the renal cell and hepatocellular carcinoma markets. Additionally, risks related to commercial performance of Cabometyx, the failure to yield favorable data from ongoing clinical trials, and looming challenges from generic competition further exacerbate uncertainties surrounding Exelixis's financial stability and long-term viability.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares